Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT

User menu

Search

  • Advanced search
eNeuro
eNeuro

Advanced Search

 

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT
PreviousNext
Research ArticleResearch Article: New Research, Disorders of the Nervous System

Neuronal Correlates of Hyperalgesia and Somatic Signs of Heroin Withdrawal in Male and Female Mice

Yocasta Alvarez-Bagnarol, Renata C. N. Marchette, Chase Francis, Marisela Morales and Leandro F. Vendruscolo
eNeuro 21 June 2022, 9 (4) ENEURO.0106-22.2022; https://doi.org/10.1523/ENEURO.0106-22.2022
Yocasta Alvarez-Bagnarol
1Neuronal Networks Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD 21224
2Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD 21224
3Department of Anatomy and Neurobiology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico 00936-5067
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yocasta Alvarez-Bagnarol
Renata C. N. Marchette
2Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD 21224
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Renata C. N. Marchette
Chase Francis
1Neuronal Networks Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD 21224
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marisela Morales
1Neuronal Networks Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD 21224
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leandro F. Vendruscolo
2Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD 21224
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leandro F. Vendruscolo
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Extended Data
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Repeated heroin injections caused mechanical hyperalgesia during withdrawal in male and female mice. A, B, Timeline and experimental procedures. Adult male and female mice were habituated for 1 h to the testing apparatus on day 1 (D1). We measured baseline paw withdrawal thresholds on D2. We gave mice twice daily subcutaneous injections of saline (10 ml/kg; nondependent) or increasing doses of heroin (5–40 mg/kg; dependent) from D3 to D5. Bodyweight loss during treatment is shown in Extended Data Figure 1-1. We tested paw withdrawal thresholds 16 h after the last heroin injection on D7 and perfused the mice 1 h later. C, We did not detect significant differences between male and female mice in paw withdrawal thresholds at baseline and 16 h into withdrawal. We found significant effects of treatment (p < 0.0001) and time (p < 0.0001) and a significant treatment × time interaction (p < 0.0001), indicating hyperalgesia in both sexes. The data are expressed as mean ± SEM n = 13–14/group. D, At 16 h into withdrawal, heroin-treated mice (males and females combined) had significant lower paw withdrawal thresholds compared with saline-treated mice (****p < 0.0001) and compared with paw withdrawal thresholds during baseline (####p < 0.0001). E, Heroin-treated mice (males and females combined) exhibited significantly higher hyperalgesia during spontaneous opioid withdrawal than saline-treated mice (****p < 0.0001). We calculated the Δ paw withdrawal threshold (paw withdrawal thresholds at baseline minus paw withdrawal thresholds at testing) to use as a single number for subsequent data analyses. The data are expressed as mean ± SEM n = 27–28/group.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Repeated heroin injections produced naloxone-precipitated somatic signs of opioid withdrawal in male and female mice. A, B, Timeline and experimental procedures. We gave mice twice daily injections of saline (10 ml/kg, s.c.) or increasing doses of heroin (10–50 mg/kg, s.c.) from D1 to D5. On D6, we gave mice a single injection of saline or heroin (50 mg/kg, s.c.). Bodyweight loss during treatment is shown in Extended Data Figure 2-1. Two hours after the saline or heroin injection, we precipitated withdrawal with a single intraperitoneal injection of the preferential μ-opioid receptor antagonist naloxone (1 mg/kg) and recorded somatic signs of withdrawal for 20 min. We perfused mice 1 h after the end of behavior scoring (i.e., 80 min after the naloxone injection). C, We did not detect significant differences between male and female mice in paw tremors or “wet-dog” shakes, but heroin-treated mice exhibited a significantly higher number of paw tremors (****p < 0.0001) and “wet-dog” shakes (****p < 0.0001) than saline-treated mice. Heroin-treated female mice exhibited a higher number of jumps compared with heroin-treated male mice (++++p < 0.0001), and heroin-treated mice of both sexes exhibited a significantly higher number of jumps compared with saline-treated mice (****p < 0.0001). D, We found an effect of treatment on opioid withdrawal scores (****p < 0.0001), with no significant differences between male and female mice. We calculated the opioid withdrawal score (sum of the number of occurrences of individual somatic signs) to use as a single number for subsequent data analyses. The data are expressed as mean ± SEM n = 11/group. E, Heroin-dependent mice (male and female data combined) exhibited a higher opioid withdrawal score than saline-treated mice (****p < 0.0001). The data are expressed as mean ± SEM n = 22/group. gf, grams of force.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Regional distribution of c-Fos-expressing neurons following the assessment of hyperalgesia during spontaneous heroin withdrawal. Significant effects of treatment on c-Fos expression were found in the PVN (****p < 0.0001), LH (***p < 0.001), CeA (****p < 0.0001), LHb (****p < 0.0001), VTA (****p < 0.0001), DR (**p < 0.01), PBN (****p < 0.0001), and LC (***p < 0.001). The data are expressed as mean ± SEM n = 11–12/group (male and female data combined). A comparison of c-Fos expression levels between heroin-treated and saline-treated male and female mice is shown in Extended Data Figure 3-1.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Regional distribution of c-Fos-expressing neurons following the assessment of naloxone-precipitated somatic signs of heroin withdrawal. Significant effects of treatment on c-Fos expression were found in the NAc shell (***p < 0.001), BNST (****p < 0.0001), PVN (****p < 0.0001), PVT (*p < 0.05), LH (****p < 0.0001), CeA (***p < 0.001), LHb (***p < 0.001), SUM (****p < 0.0001), VTA (***p < 0.001), DR (**p < 0.01), PBN (****p < 0.0001), and LC (****p < 0.0001). The data are expressed as mean ± SEM n = 11/group (male and female data combined). A comparison of c-Fos expression levels between heroin-treated and saline-treated male and female mice is shown in Extended Data Figure 4-1.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Hyperalgesia during spontaneous heroin withdrawal and naloxone-precipitated somatic signs of heroin withdrawal were associated with c-Fos expression in specific brain areas. A, PCA of hyperalgesia and c-Fos expression in different brain regions in heroin-dependent mice. Hyperalgesia (red circle) and the DR, LC, CeA, VTA LH, and PBN (purple circles) loaded onto the PC1. The BNST, PVT, NAc shell, SUM, and PAG loaded onto the PC2 (green circles). Bodyweight loss (BW) and the PVN (black circles) loaded independently from PC1 and PC2. The distributions of variables are shown along the two factors (independent axes) with factor loadings ≥0.7 (indicated by dotted lines), produced by an orthogonal normalized varimax rotation. n = 12/group (male and female data combined). B, PCA of somatic withdrawal and Fos expression in different brain regions in heroin-dependent mice. The LH, SUM, PBN, BNST, NAc shell, and CeA (green circles) loaded onto PC1. Somatic withdrawal (red circle) and the DR, LC, LHb, and PVT (blue circles) loaded onto PC2. The BW, PVN, VTA, and PAG (black circles) loaded independently from PC1 and PC2. The distributions of variables are shown along the two factors with factor loadings ≥0.7, produced by an orthogonal normalized varimax rotation. n = 11/group (male and female data combined). C, Correlation of c-Fos expression in specific brain regions in heroin-dependent mice following the assessment of hyperalgesia during spontaneous withdrawal. Pearson correlation coefficients (r) inside the boxes correspond to regions that showed significant correlations (p < 0.05). Darker purple shades represent stronger correlations. n = 12/group (male and female data combined). D, Correlations of c-Fos expression in specific brain regions in heroin-dependent mice following the assessment of naloxone-precipitated somatic signs of heroin withdrawal. Pearson correlation coefficients (r) inside the boxes correspond to regions that showed significant correlations (p < 0.05). Darker green shades represent stronger correlations. n = 11/group (male and female data combined).

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Summary of brain regions that are associated with neuronal c-Fos expression following the assessment of hyperalgesia during spontaneous withdrawal or naloxone-precipitated somatic signs of withdrawal in heroin-dependent mice. The colored brain regions were associated with PCA factors that loaded with hyperalgesia (purple), somatic signs of withdrawal (green), or both (purple/green) in heroin-dependent mice. The PBN, VTA, LH, and CeA are potentially involved in the expression of hyperalgesia during spontaneous withdrawal from heroin. The PVT and LHb are potentially involved in somatic signs of naloxone-precipitated heroin withdrawal. The DR and LC may play a role in both hyperalgesia and somatic signs of heroin withdrawal. The connecting lines represent significant correlations of c-Fos expression in brain regions that were associated with PCA factors that loaded with the behavior. The thickness of the lines represents the strength of correlations (thin = low correlation, r < 0.84; thick = high correlation, r > 0.84).

Tables

  • Figures
  • Extended Data
    • View popup
    Table 1

    Two-way ANOVA results of Fos quantification in analyzed brain regions following hyperalgesia during spontaneous withdrawal

    Brain regionTreatment effectSex effectSex × treatment interaction
    NAc shellF(1,19) = 0.8349, p = 0.3723F(1,19) = 10.41, p = 0.0044; F > MF(1,19) = 0.05892, p = 0.8108
    BNSTF(1,19) = 1.926, p = 0.1813F(1,19) = 4.275, p = 0.0526F(1,19) = 0.4395, p = 0.5153
    PVNF(1,19) = 30.16, p < 0.0001F(1,19) = 8.964, p = 0.0075; F > MF(1,19) = 0.2445, p = 0.1344
    PVTF(1,19) = 0.1164, p = 0.7367F(1,19) = 2.544, p = 0.1272F(1,19) = 0.2627, p = 0.6142
    LHF(1,19) = 16.93, p < 0.001F(1,19) = 5.546, p = 0.0294; F > MF(1,19) = 0.1327, p = 0.7197
    CeAF(1,19) = 26.37, p < 0.0001F(1,19) = 1.876, p = 0.1867F(1,19) = 0.09373, p = 0.7628
    LHbF(1,19) = 40.80, p < 0.0001F(1,19) = 8.195, p = 0.0100; F > MF(1,19) = 0.9071, p = 0.3528
    PAGF(1,19) = 1.136, p = 0.2998F(1,19) = 8.589, p = 0.0086; F > MF(1,19) = 0.005, p = 0.9441
    SUMF(1,19) = 4.195, p = 0.0546F(1,19) = 14.44, p = 0.0012; F > MF(1,19) = 0.007174, p = 0.9334
    VTAF(1,19) = 27.39, p < 0.0001F(1,19) = 5.773, p = 0.0267; F > MF(1,19) = 0.1231, p = 0.2810
    DRF(1,19) = 11.70, p < 0.01F(1,19) = 1.803, p = 0.1952F(1,19) = 0.08641, p = 0.3642
    PBNF(1,19) = 26.15, p < 0.0001F(1,19) = 0.2822, p = 0.6014F(1,19) = 0.1759, p = 0.6796
    LCF(1,19) = 17.91, p < 0.001F(1,19) = 0.5460, p = 0.4695F(1,19) = 0.5909, p = 0.4520
    • Males (M), Females (F).

    • View popup
    Table 2

    Two-way ANOVA results of Fos quantification in analyzed brain regions following naloxone-precipitated somatic signs of opioid withdrawal

    Brain regionTreatment effectSex effectSex × treatment interaction
    NAc shellF(1,18) = 15.91, p < 0.001F(1,18) = 40.50, p < 0.0001; M > FF(1,18) = 1.781, p = 0.1986
    BNSTF(1,18) = 29.53, p < 0.0001F(1,18) = 14.97, p = 0.0011; M > FF(1,18) = 1.470, p = 0.2411
    PVNF(1,18) = 43.11, p < 0.0001F(1,18) = 1.915, p = 0.1833F(1,18) = 0.1469, p = 0.7060
    PVTF(1,18) = 5.069, p < 0.05F(1,18) = 4.738, p = 0.0431; F > MF(1,18) = 1.023, p = 0.3253
    LHF(1,18) = 30.28, p < 0.001F(1,18) = 0.3534, p = 0.5436F(1,18) = 0.04941, p = 0.8266
    CeAF(1,18) = 17.40, p < 0.001F(1,18) = 23.89, p = 0.0001; M > FF(1,18) = 3.703, p = 0.0703
    LHbF(1,18) = 18.28, p < 0.001F(1,18) = 8.314, p = 0.0099; F > MF(1,18) = 1.297, p = 0.2697
    PAGF(1,18) = 3.855, p = 0.0652F(1,18) = 0.02565, p = 0.8746F(1,18) = 0.3041, p = 0.5881
    SUMF(1,18) = 33.96, p < 0.0001F(1,18) = 1.128, p = 0.3023F(1,18) = 6.029, p = 0.0245
    VTAF(1,18) = 24.40, p < 0.0001F(1,18) = 2.406, p = 0.1383F(1,18) = 1.791, p = 0.1975
    DRF(1,18) = 14.54, p < 0.01F(1,18) = 12.91, p = 0.0021; F > MF(1,18) = 0.116, p = 0.7422
    PBNF(1,18) = 27.17, p < 0.0001F(1,18) = 18.16, p = 0.0005; M > FF(1,18) = 0.1257, p = 0.7271
    LCF(1,18) = 88.91, p < 0.0001F(1,18) = 29.03, p < 0.0001; F > MF(1,18) = 2.218, p = 0.1537
    • Males (M), Females (F).

Extended Data

  • Figures
  • Tables
  • Extended Data Figure 1-1

    Repeated heroin injections caused bodyweight loss in male and female mice. Percent of bodyweight change in mice that were used for the c-Fos expression experiment following the assessment of hyperalgesia during spontaneous heroin withdrawal. The Student’s t test showed that heroin-treated mice (male and female data combined) weighed significantly less than saline-treated mice (****p < 0.0001). The data are expressed as mean ± SEM. N = 12/group. Download Figure 1-1, TIF file.

  • Extended Data Figure 2-1

    Repeated heroin injections caused bodyweight loss in male and female mice. Percent of bodyweight change in mice used for the c-Fos expression experiment following the assessment of naloxone-precipitated somatic signs of opioid withdrawal. The Student’s t test showed that heroin-treated mice (male and female data combined) weighed significantly less than saline mice (****p < 0.0001). The data are expressed as mean ± SEM. N = 12/group. Download Figure 2-1, TIF file.

  • Extended Data Figure 3-1

    C-Fos expression in neurons distributed in distinct brain regions in male and female mice following the assessment of hyperalgesia during spontaneous heroin withdrawal. Two-way ANOVAs showed no sex × treatment interactions for any of the analyzed brain regions. We found main treatment effect and main sex effect on the number c-Fos-expressing neurons in several brain regions: LH (treatment effect: F(1,19) = 16.93, p < 0.001; sex effect: F(1,19) = 5.546, p = 0.0294; sex × treatment interaction: F(1,19) = 0.1327, p = 0.7197), LHb (treatment effect: F(1,19) = 40.80, p < 0.0001; sex effect: F(1,19) = 8.195, p = 0.0100; sex × treatment interaction: F(1,19) = 0.9071, p = 0.3528), VTA (treatment effect: F(1,19) = 27.39, p < 0.0001; sex effect: F(1,19) = 5.773, p = 0.0267; sex × treatment interaction: F(1,19) = 0.1231, p = 0.2810), PVN (treatment effect: F(1,19) = 30.16, p < 0.0001; sex effect: F(1,19) = 8.964, p = 0.0075; sex × treatment interaction: F(1,19) = 0.2445, p = 0.1344), and SUM (treatment effect: F(1,19) = 4.195, p = 0.0546; sex effect: F(1,19) = 14.44, p = 0.0012; sex × treatment interaction: F(1,19) = 0.007174, p = 0.9334). We found significant treatment effect but no sex effect in the following brain regions: CeA (treatment effect: F(1,19) = 26.37, p < 0.0001; sex effect: F(1,19) = 1.876, p = 0.1867; sex × treatment interaction: F(1,19) = 0.09373, p = 0.7628), DR (treatment effect: F(1,19) = 11.70, p < 0.01; sex effect: F(1,19) = 1.803, p = 0.1952; sex × treatment interaction: F(1,19) = 0.08641, p = 0.3642), PBN (treatment effect: F(1,19) = 26.15, p < 0.0001; sex effect: F(1,19) = 0.2822, p = 0.6014; sex × treatment interaction: F(1,19) = 0.1759, p = 0.6796), and LC (treatment effect: F(1,19) = 17.91, p < 0.001; sex effect: F(1,19) = 0.5460, p = 0.4695; sex × treatment interaction: F(1,19) = 0.5909, p = 0.4520). We did not find significant treatment effects, but we found main sex effects on the number of c-Fos-expressing neurons in three brain regions: NAc shell (treatment effect: F(1,19) = 0.8349, p = 0.3723; sex effect: F(1,19) = 10.41, p = 0.0044; sex × treatment interaction: F(1,19) = 0.05892, p = 0.8108), BNST (treatment effect: F(1,19) = 1.926, p = 0.1813; sex effect: F(1,19) = 4.275, p = 0.0526; sex × treatment interaction: F(1,19) = 0.4395, p = 0.5153), and PAG (treatment effect: F(1,19) = 1.136, p = 0.2998; sex effect: F(1,19) = 8.589, p = 0.0086; sex × treatment interaction: F(1,19) = 0.005, p = 0.9441). We did not find a main treatment effect nor sex effect in the PVT (treatment effect: F(1,19) = 0.1164, p = 0.7367; sex effect: F(1,19) = 2.544, p = 0.1272; sex × treatment interaction: F(1,19) = 0.2627, p = 0.6142). Download Figure 3-1, TIF file.

  • Extended Data Figure 4-1

    C-Fos expression in neurons distributed in distinct brain regions in male and female mice following the assessment of naloxone-precipitated somatic signs of heroin withdrawal. B. Two-way ANOVAs for each brain region showed a significant sex × treatment interaction only for the SUM (treatment effect: F(1,18) = 33.96, p < 0.0001; sex effect: F(1,18) = 1.128, p = 0.0245; sex × treatment interaction: F(1,18) = 6.029, p = 0.0245), but the post hoc comparisons did not detect meaningful differences (heroin females > saline males; heroin males > saline females). We found main treatment effect and main sex effect on the number of c-Fos-expressing neurons in several brain regions: NAc shell (treatment effect: F(1,18) = 15.91, p < 0.001; sex effect: F(1,18) = 40.50, p < 0.0001; sex × treatment interaction: F(1,18) = 1.781, p = 0.1986), BNST (treatment effect: F(1,18) = 29.53, p < 0.0001; sex effect: F(1,18) = 14.97, p = 0.0011; sex × treatment interaction: F(1,18) = 1.470, p = 0.2411), PVT (treatment effect: F(1,18) = 5.069, p < 0.05; sex effect: F(1,18) = 4.738, p = 0.0431; sex × treatment interaction: F(1,18) = 1.023, p = 0.3253), CeA (treatment effect: F(1,18) = 17.40, p < 0.001; sex effect: F(1,18) = 23.89, p = 0.0001; sex × treatment interaction: F(1,18) = 3.703, p = 0.0703), LHb (treatment effect: F(1,18) = 18.28, p < 0.001; sex effect: F(1,18) = 8.314, p = 0.0099; sex × treatment interaction: F(1,18) = 1.297, p = 0.2697), DR (treatment effect: F(1,18) = 14.54, p < 0.01; sex effect: F(1,18) = 12.91, p = 0.0021; sex × treatment interaction: F(1,18) = 0.116, p = 0.7422), PBN (treatment effect: F(1,18) = 27.17, p < 0.0001; sex effect: F(1,18) = 18.16, p = 0.0005; sex × treatment interaction: F(1,18) = 0.1257, p = 0.7271), and LC (treatment effect: F(1,18) = 88.91, p < 0.0001; sex effect: F(1,18) = 29.03, p < 0.0001; sex × treatment interaction: F(1,18) = 2.218, p = 0.1537). We found significant treatment effect but no sex effect in the following brain regions: PVN (treatment effect: F(1,18) = 43.11, p < 0.0001; sex effect: F(1,18) = 1.915, p = 0.1833; sex × treatment interaction: F(1,18) = 0.1469, p = 0.7060), LH (treatment effect: F(1,18) = 30.28, p < 0.001; sex effect: F(1,18) = 0.3534, p = 0.5436; sex × treatment interaction: F(1,18) = 0.04941, p = 0.8266), SUM (treatment effect: F(1,18) = 33.96, p < 0.0001; sex effect: F(1,18) = 1.128, p = 0.3023; sex × treatment interaction: F(1,18) = 6.029, p = 0.0245), and VTA (treatment effect: F(1,18) = 24.40, p < 0.0001; sex effect: F(1,18) = 2.406, p = 0.1383; sex × treatment interaction: F(1,18) = 1.791, p = 0.1975), We did not find a main treatment effect nor sex effect in the in the PAG (treatment effect: F(1,18) = 3.855, p = 0.0652; sex effect: F(1,18) = 0.02565, p = 0.8746; sex × treatment interaction: F(1,18) = 0.3041, p = 0.5881). Download Figure 4-1, TIF file.

  • Extended Data

    Macros used for preprocessing and for morphological segmentation of images using Image-Pro 10.0 software. Download Extended Data 1, DOCX file.

Back to top

In this issue

eneuro: 9 (4)
eNeuro
Vol. 9, Issue 4
July/August 2022
  • Table of Contents
  • Index by author
  • Ed Board (PDF)
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Neuronal Correlates of Hyperalgesia and Somatic Signs of Heroin Withdrawal in Male and Female Mice
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Neuronal Correlates of Hyperalgesia and Somatic Signs of Heroin Withdrawal in Male and Female Mice
Yocasta Alvarez-Bagnarol, Renata C. N. Marchette, Chase Francis, Marisela Morales, Leandro F. Vendruscolo
eNeuro 21 June 2022, 9 (4) ENEURO.0106-22.2022; DOI: 10.1523/ENEURO.0106-22.2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Neuronal Correlates of Hyperalgesia and Somatic Signs of Heroin Withdrawal in Male and Female Mice
Yocasta Alvarez-Bagnarol, Renata C. N. Marchette, Chase Francis, Marisela Morales, Leandro F. Vendruscolo
eNeuro 21 June 2022, 9 (4) ENEURO.0106-22.2022; DOI: 10.1523/ENEURO.0106-22.2022
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Significance Statement
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
    • Synthesis
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • neuronal activity
  • opioids
  • pain
  • reinforcement
  • reward
  • stress

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Research Article: New Research

  • Action intentions reactivate representations of task-relevant cognitive cues
  • Interference underlies attenuation upon relearning in sensorimotor adaptation
  • Transformed visual working memory representations in human occipitotemporal and posterior parietal cortices
Show more Research Article: New Research

Disorders of the Nervous System

  • Gene variants related to primary familial brain calcification: perspectives from bibliometrics and meta-analysis
  • Expression of HDAC3-Y298H Point Mutant in Medial Habenula Cholinergic Neurons Has No Effect on Cocaine-Induced Behaviors
  • Parallel Gene Expression Changes in Ventral Midbrain Dopamine and GABA Neurons during Normal Aging
Show more Disorders of the Nervous System

Subjects

  • Disorders of the Nervous System
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2025 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.